Amerisource Health Services Initiates Class II Recall of Oxycodone Hydrochloride Due to Packaging Defects
Amerisource Health Services LLC initiated a Class II recall for 31,676 packages of Oxycodone Hydrochloride Tablets due to defective blister card seals. This nationwide recall, impacting lots 1027932 and 1028360, poses significant supply chain risks for procurement and regulatory teams. Businesses must assess their exposure to packaging quality vulnerabilities and reinforce supplier qualification protocols to mitigate disruption and ensure patient safety.
FDA Class II Recall: Amerisource Health Services' Oxycodone Hydrochloride Packaging Failure
Amerisource Health Services LLC, based in Columbus, Ohio, has initiated a voluntary Class II recall for 31,676 packages of Oxycodone Hydrochloride Tablets, USP (CII), 5 mg. This critical action, identified by recall number D-0338-2026, stems from significant container defects where blister card seals were found to be weak or non-existent, causing tablets to fall out of their cavities. For procurement directors and supply chain VPs, this defect directly impacts product integrity and patient safety, raising concerns about potential dose loss or, more critically for a Schedule II controlled substance, diversion. The affected product, distributed nationwide in the USA, includes lots 1027932 with an expiration date of June 30, 2027, and 1028360 expiring on August 31, 2027. The drug product contained in these packages originates from NDC #10702-018, supplied by KVK-Tech Inc., and was distributed by American Health Packaging under Carton NDC 68084-354-01 and Blister NDC 68084-354-11. This incident underscores the paramount importance of robust quality control throughout the entire packaging process, as failures at this stage can lead to substantial recall costs, reputational damage, and potential regulatory scrutiny beyond the immediate recall.
Supply Chain Exposure: Nationwide Distribution of Defective Controlled Substances
The nationwide distribution of 31,676 packages of defective Oxycodone Hydrochloride Tablets presents a significant challenge for supply chain resilience and regulatory compliance across the United States. For procurement directors, this event highlights the imperative of scrutinizing not only active pharmaceutical ingredient (API) suppliers but also contract packaging organizations (CPOs) like KVK-Tech Inc. and distributors such as American Health Packaging. A Class II recall, indicating a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, still necessitates immediate action from all downstream partners. Supply chain VPs must now manage the logistical complexities of retrieving affected inventory, ensuring proper segregation, and coordinating returns, all while maintaining continuity of supply for a critical pain management medication. The financial implications extend beyond direct recall costs to include potential stockouts, expedited shipping for replacement products, and the administrative burden of managing customer notifications and regulatory reporting. This incident serves as a stark reminder that packaging quality is as crucial as product formulation in safeguarding both patient welfare and commercial operations.
Regulatory Landscape: Broader Trends in Pharmaceutical Quality Control and Packaging Integrity
This recall by Amerisource Health Services LLC for Oxycodone Hydrochloride Tablets is not an isolated incident but rather reflects a broader trend of quality control challenges within the pharmaceutical industry. Recent parallel events highlight ongoing vulnerabilities in manufacturing and packaging processes. For instance, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection due to sterility assurance failures, and Spectra Medical Devices experienced a similar Class II recall for Lidocaine HCl Injection, also related to sterility deficiencies. Furthermore, Guardian Drug Co. Inc. initiated nationwide Class II recalls for Tums Antacid and Calcium Carbonate Antacids due to metallic contamination. These diverse issues, ranging from sterility to foreign matter and now packaging integrity, collectively signal an environment where regulatory bodies like the FDA are intensely focused on comprehensive quality systems. For regulatory affairs heads, this pattern necessitates a proactive review of all quality agreements with contract manufacturers and packagers, ensuring that robust in-process controls and final product release criteria are rigorously enforced. The commercial implication is clear: companies failing to maintain stringent quality oversight across their entire product lifecycle risk not only recalls but also potential Warning Letters, import alerts, and significant market access restrictions, impacting long-term business development strategies.
Risk Mitigation Strategies for Pharmaceutical Procurement and Regulatory Teams
In light of the Amerisource Health Services recall, procurement directors and regulatory affairs heads must implement enhanced risk mitigation strategies to protect their supply chains and ensure product quality. Firstly, conduct a thorough review of all existing supplier qualification programs, particularly for products involving blister packaging or other complex primary packaging formats. This should include on-site audits of contract manufacturing organizations (CMOs) and contract packaging organizations (CPOs) to assess their quality management systems, specifically focusing on packaging line integrity, seal verification processes, and material handling. Secondly, strengthen quality agreements to include explicit clauses detailing packaging specifications, acceptable defect rates, and clear responsibilities for quality deviations. For business development executives, diversifying the supplier base for critical molecules like Oxycodone Hydrochloride is paramount, even if specific alternative suppliers were not identified in this immediate intelligence brief. While the knowledge graph did not provide alternative suppliers for Oxycodone Hydrochloride, proactive identification and qualification of secondary and tertiary sources can prevent significant supply disruptions during recall events. Finally, implement robust incoming material inspection protocols for all packaging components and finished goods, utilizing advanced inspection technologies to detect subtle defects before products enter the distribution network. These proactive measures are essential to safeguard patient safety, maintain market access, and preserve brand reputation.
Remediation and Future Compliance Expectations for Amerisource Health Services
The recall of Oxycodone Hydrochloride Tablets by Amerisource Health Services LLC, initiated voluntarily by the firm on January 14, 2026, and classified by the FDA on February 13, 2026, remains an ongoing event. This status indicates that the FDA is actively monitoring the effectiveness of the recall and Amerisource Health Services' corrective and preventive actions (CAPA) plan. For regulatory affairs heads, understanding the FDA's expectations in such scenarios is crucial. The agency will require a comprehensive investigation into the root cause of the weak or non-existent card seals, which led to tablets falling out of their cavities. This investigation must extend to the original packager, KVK-Tech Inc., and the distributor, American Health Packaging, to identify systemic issues. Amerisource Health Services will need to demonstrate that robust corrective actions have been implemented to prevent recurrence, including potential modifications to packaging equipment, process controls, or quality assurance procedures. Failure to adequately address these issues could lead to further regulatory enforcement actions, such as a Warning Letter or even an injunction, significantly impacting the company's ability to market pharmaceutical products. Other companies should leverage this event as an opportunity to review their own supplier oversight mechanisms and internal packaging quality controls, ensuring they are prepared to demonstrate compliance and mitigate similar risks.